Pfizer has postponed filing for FDA approval of its COVID-19 vaccination for children younger than 5 years old, the company revealed on Friday. The meeting with the FDA was originally scheduled for February 15, but the business postponed it so that it could collect more clinical trial data for a three-dose regimen rather than the two-dose schedule it had requested. Pfizer believes a third dose will generate a more robust immune response in young children based on the outcomes of the trials with two doses.
Parents of small children who have been waiting impatiently for the opportunity to vaccinate their children will be disappointed to hear this news. Pfizer’s COVID-19 vaccine was given FDA approval in May 2021 for use in children ages 12 to 15, and again in late October 2021 for use in children ages 5 to 11. Currently, the age 5 cutoff for receiving the COVID-19 vaccine has not been reached.
Hospitalizations of young, unvaccinated children surged during the Omicron surge, and parents of infants, toddlers, and preschoolers waited months for assurances that their children would be protected from the worst effects of COVID-19.
Study of Pfizer’s COVID-19 Vaccine in Young Children
After an outbreak of Omicron virus infections in early February, the Food and Drug Administration (FDA) requested trial data for EUA of the vaccination in young children from Pfizer. With the availability of trial results, a third dose of the vaccine might be offered for maximum protection, but in the meanwhile, the two-dose vaccine could be administered to children aged 2 to 4.
Pfizer’s three-dose trial progressed more quickly than anticipated. Thus the original strategy had to be revised. They felt certain that the trial data could be collected in less time and that it would demonstrate an enhanced immune response.
Pfizer and BioNTech continue to believe it may provide a better level of protection in this age range, but they will wait for the three-dose data until the research is complete.
The shift in strategy has nothing to do with any defects in the vaccination. Rather, the focus is on optimizing the vaccine’s efficacy. Babies 6–24 months old and toddlers and preschoolers ages 2–4 were the subjects of the earliest immunization studies. Pfizer’s vaccine was administered in two 3 µg doses, one 21 days apart, to each age group.
Compared to the dosage provided to children aged 5-11 (10 µg) and those aged 12-15 (30 µg), this was significantly lower. After receiving the 3µg dose, no adverse effects were observed in either the 6- to 24-month or the 2- to 4-year-old groups.
Pfizer claims that infants given a 3 µg dosage of vaccination had an immunological response comparable to that seen in healthy adults aged 16–25 after receiving the vaccine. But kids aged 2–4 had a weaker immunological response. Pfizer stopped the study temporarily to investigate if a third, 3 µg dose would yield better outcomes in the 2- to 4-year-old group. Pfizer claims it hopes to rapidly collect fresh data, with results from the three-dose experiment due by early April 2022.
The trial was initially stopped because of the lack of antibody protection shown with the lower COVID-19 vaccination dose in this age range. Pfizer was concerned about providing a safe vaccine for children while also providing them with the same level of protection as other groups.
An Overview of the Value of the COVID-19 Vaccine for Young Children
However, experts agree that the need for a vaccine for younger children remains urgent despite Pfizer’s decision to delay its application for a vaccine. Most kids recover quickly from a case of COVID-19, but unvaccinated kids, in particular, are at risk for serious complications. This was found in New York during the Omicron surge, when the state health department noted a significant uptick in pediatric hospitalizations.
Hospitalizations of children due to COVID-19 increased eighteenfold in New York City alone. The vast majority of kids hospitalized across the state had not been immunized. More than half of the hospitalized kids were less than four, making them an age group that was previously ineligible for immunization.
Having a vaccination that protects young children from the virus will provide parents peace of mind that their children are protected from the illness’s potentially devastating effects. These reassurances were formerly reserved for children aged 5 and up.
If this vaccine were approved, everyone in a household could get vaccinated against COVID-19, with the exception of infants younger than six months old.
And because of the dramatic increase in infections among children during the Omicron wave, parents also had to contend with the shutdown of daycares and preschools, as well as quarantines and isolation periods. All of these were quite inconvenient for mom and dad and the kids.
By providing protection against disease, vaccines help kids get back to a more typical existence. They are able to reduce the impact of COVID-19 on their life and their families by attending normal activities like daycare, preschool, classes, trips, and birthday parties.
It’s natural for parents to ask what this means for the vaccine’s efficacy and safety. It’s important to keep in mind that scientists are being as cautious and thorough as they can be in rolling out this vaccination by waiting for further evidence and making sure vaccines are as effective as possible.
A parent who was looking forward to giving their young kid the immunization may now feel discouraged and upset. However, keep in mind that the vaccine is projected to arrive in a matter of months. Meanwhile, you can keep your youngster safe by using techniques like social isolation and disguising.
Articles you might like: Pfizer’s Covid-19 Vaccine Licensed For Use In Children 5-11 Years Old, Clinical Trial Shows Pfizer-Biontech Vaccine Safe & Effective For Ages 12-15, Should You Vaccinate Your Children With Pfizer or Moderna?